## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.7% below STRENGTH zone (3.0-6.0%); PEG 1.67 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($36.19)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 2)

**1. |Centene stock rating reiterated at Neutral by Cantor Fitzgerald**
- Source: Investing.com | 20251219T140800 | Neutral | Relevance: 100%
- |Cantor Fitzgerald reiterated its Neutral rating and $41.00 price target for Centene (NYSE:CNC), suggesting the stock may be undervalued at its current price based on InvestingPro's Fair Value. The firm's analysis, following a fourth-quarter 2025 Private Hospital Executive Survey, indicates strengthening volumes and provider optimism for 2026, which could benefit Centene. Despite increased confidence in core strength, Cantor Fitzgerald noted ongoing policy headline risks for the healthcare company.

**2. Does ACA Subsidy Uncertainty Reshape Centene’s Government Programs Story And Prevention Focus (CNC)?**
- Source: Simply Wall Street | 20251219T093708 | Somewhat-Bearish | Relevance: 100%
- Reports of potential non-renewal of Affordable Care Act premium subsidies are raising concerns about Centene's ACA marketplace exposure and the profitability of health insurers. This uncertainty challenges Centene's investment narrative, which relies on government-backed health programs for growth, despite the company's focus on preventive care and member engagement. Investors need to consider the impact of expiring subsidies on Centene's future earnings and the stability of the Marketplace.

**3. Assenagon Asset Management S.A. Sells 385,957 Shares of Centene Corporation $CNC**
- Source: MarketBeat | 20251218T082156 | Somewhat-Bearish | Relevance: 100%
- Assenagon Asset Management S.A. reduced its stake in Centene Corporation (NYSE:CNC) by 21.0% in the third quarter, selling 385,957 shares and retaining 1,450,470 shares valued at approximately $51.75 million. Despite stronger-than-expected recent quarterly results, Centene posted a negative net margin and currently holds a "Hold" rating from analysts with an average target price of $38.44, while trading around $38.86. Institutional investors maintain a significant ownership of 93.63% in the company.

**4. Ambetter Health & Tampa Bay Buccaneers Launch "Stay Healthy, Stay in the Game" PSA Urging Floridians to Prioritize Preventive Care Before Year-End – Company Announcement - FT.com**
- Source: Financial Times | 20251217T200100 | Bullish | Relevance: 100%
- Ambetter Health and the Tampa Bay Buccaneers have collaborated on a new public service announcement (PSA) called "Stay Healthy, Stay in the Game." This campaign encourages Floridians to prioritize preventive care, routine screenings, and year-end checkups, featuring Buccaneers players who highlight the importance of proactive health management. The initiative aims to motivate individuals to take charge of their health for a better quality of life.

**5. Paralympian Dana Mathewson joins new campaign to boost Florida health**
- Source: Stock Titan | 20251217T180154 | Bullish | Relevance: 100%
- Sunshine Health, a Centene Corporation company, announced a partnership with elite female athletes, including Paralympian Dana Mathewson, to promote health awareness across Florida. This collaboration with sports marketing partner Parity focuses on prevention, mental health, child and maternal health, and community wellness. Sunshine Health will utilize its 10 Community Connections Centers to provide outreach, education, and resources to Medicaid members statewide.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Bernstein | $45 | $36 | +25% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Bernstein | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-5.9% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 10.2% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.67 elevated, pricing in significant growth expectations. Forward P/E 13.5x attractive for 43% earnings growth. Balance sheet: $1.1B free cash flow. Analyst sentiment positive (1 raises, avg +25%). Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.2B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.67 |
| Forward P/E | 13.5 |
| Current P/E | 19.3 |
| YoY Growth | 43.0% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 5.2% to -0.7% (-5.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.7pp (needs >3.0% for momentum thesis). Below SMA200 (0.90x), long-term trend not supportive. RSI neutral at 54. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.71% (CS: 41) | Neutral |
| RSI_14 | 54.1 | Neutral |
| MACD Histogram | -0.10 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.056x | Above |
| vs SMA200 | 0.898x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $39.03
- **Stop Loss:** $36.19 (7.3% risk)
- **Target:** $41.87 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 422
- **Position Value:** $16,470.66
- **Portfolio %:** 16.47%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*